Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes.
about
Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozinEmpagliflozin in the treatment of type 2 diabetes: evidence to dateShort commentary on empagliflozin and its potential clinical impactThe Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 DiabetesEuglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 InhibitionDapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus.The renal effects of SGLT2 inhibitors and a mini-review of the literature.Natural product and natural product derived drugs in clinical trials.Management of Severe Insulin Resistance in Patients with Type 1 Diabetes.The treatment of type 1 diabetes mellitus with agents approved for type 2 diabetes mellitus.Current management of diabetes mellitus and future directions in care.SGLT-2 Inhibitors: Is There a Role in Type 1 Diabetes Mellitus Management?Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes.Dapagliflozin for the treatment of type 1 diabetes mellitus.Use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus.Pharmacological Treatment in Diabetes Mellitus Type 1 - Insulin and What Else?
P2860
Q28250844-E239BD30-7C14-45BD-B508-B0AADE62B31BQ34502358-4491F83F-9FC7-4364-A942-A840E3DE6118Q35528797-C0892AB4-8BA7-4C60-874C-E656236091EEQ35903101-02F61DC4-0C3E-4ED7-921D-FA2BC28BACD7Q35973255-80C61A98-EEC6-4843-A694-32567F39B328Q36144090-17F3582D-61E1-47A1-89B4-BE7C779BE146Q37632127-E885B7F4-9DEC-41A4-A9BB-2F8FC56F79D2Q38247457-8633362D-F7F8-4164-99E8-AEEE9ED9B67EQ38570757-086447EC-2972-49D2-A694-DEF831DA0494Q38580783-BE1FB9D9-47CA-4747-BDE4-6AEFC89C5FCAQ38603504-66951684-8688-4820-B96C-99E89B80EBB3Q38768667-AEBA4065-6554-41AF-AD1C-62DE7E9003A6Q39000172-89896CBE-BCCF-4166-A76E-85DE04E93DD5Q39354776-2F4DC13F-1241-4B6E-A9B0-888BFFBA8E83Q47700645-BE023050-C664-494D-8C5F-7BE1809A87F3Q52562630-E2362F73-5F87-4D04-91DF-9B8570F3C1E2
P2860
Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Empagliflozin, a sodium glucos ...... treatment of type 1 diabetes.
@en
type
label
Empagliflozin, a sodium glucos ...... treatment of type 1 diabetes.
@en
prefLabel
Empagliflozin, a sodium glucos ...... treatment of type 1 diabetes.
@en
P2093
P2860
P1476
Empagliflozin, a sodium glucos ...... treatment of type 1 diabetes.
@en
P2093
Elizabeth M Lamos
Lisa M Younk
Stephen N Davis
P2860
P304
P356
10.1517/13543784.2014.909407
P407
P577
2014-04-19T00:00:00Z